Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs
The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.
1. A method for treatment and/or prophylaxis of allergic dermatitis in a non-human animal comprising administering to the non-human animal an effective amount of compound having the structure:
or a metabolite, a salt, a solvate, a solvate of the salt thereof.
2. The method according to claim 1 , wherein the allergic dermatitis is atopic dermatitis.
3. The method according to claim 2 , wherein the method is treatment of atopic dermatitis.
4. The method according to claim 1 , wherein the allergic dermatitis is allergic contact dermatitis.
5. The method according to claim 4 , wherein the method is treatment of allergic contact dermatitis.
6. The method according to claim 1 , wherein the method is treatment, and the allergic dermatitis is atopic dermatitis or allergic contact dermatitis.
7. The method according to claim 1 , wherein the compound is administered to the non-human animal in a dosage form comprising at least one pharmaceutically suitable excipient.
8. The method according to claim 3 , wherein the compound is administered to the non-human animal in a dosage form comprising at least one pharmaceutically suitable excipient.
9. The method according to claim 5 , wherein the compound is administered to the non-human animal in a dosage form comprising at least one pharmaceutically suitable excipient.